Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?
M T Corkum, V Achard, G Morton, T Zilli, M T Corkum, V Achard, G Morton, T Zilli
Abstract
Following adoption of moderately hypofractionated radiotherapy as a standard for localised prostate cancer, ultrahypofractioned radiotherapy delivered in five to seven fractions is rapidly being embraced by clinical practice and international guidelines. However, the question remains: how low can we go? Can radiotherapy for prostate cancer be delivered in fewer than five fractions? The current review summarises the evidence that radiotherapy for localised prostate cancer can be safely and effectively delivered in fewer than five fractions using high dose rate brachytherapy or stereotactic body radiotherapy. We also discuss important lessons learned from the single-fraction high dose rate brachytherapy experience.
Trial registration: ClinicalTrials.gov NCT03569241.
Keywords: Dose fractionation; high dose rate brachytherapy; prostate cancer; stereotactic body radiotherapy.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Source: PubMed